Shares of Revolution Medicines, Inc. (RVMD) are climbing about 39 percent on Monday morning trading after the company announced positive topline data from the Phase 3 RASolute trial for Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma.
The company's shares are currently trading at $134.58 on the Nasdaq, up 39.34 percent. The stock opened at $132.41 and has climbed as high as $135.00 so far in today's session. Over the past year, it has traded in a range of $34.00 to $135.00.
The drug demonstrated improved progression-free survival and overall survival in the patients by statistically significant and clinically meaningful margins.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.